Aktienanalyse wird geladen …
AMGN · NASDAQ · Biotechnology · USA
406,08 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 36,75 Mrd. | 7,71 Mrd. | 14,23 $ | 542 Mio. | 1,2 Mio · 0,2 % | 0,2 Mio · 0 % | 67,3 % | 21 % | 14,94 $ | 0,91 $ | 9,66 $ |
| 2024 | 33,42 Mrd. | 4,09 Mrd. | 7,56 $ | 541 Mio. | 1,3 Mio · 0,2 % | — | 61,5 % | 12,2 % | 19,21 $ | 0,98 $ | 9,13 $ |
| 2023 | 28,19 Mrd. | 6,72 Mrd. | 12,49 $ | 538 Mio. | 1,1 Mio · 0,2 % | 4,1 Mio · 0,8 % | 70 % | 23,8 % | 13,68 $ | 0,80 $ | 8,64 $ |
| 2022 | 26,32 Mrd. | 6,55 Mrd. | 12,11 $ | 541 Mio. | 1 Mio · 0,2 % | 33 Mio · 6,1 % | 75,7 % | 24,9 % | 16,24 $ | 0,74 $ | 7,95 $ |
| 2021 | 25,98 Mrd. | 5,89 Mrd. | 10,28 $ | 573 Mio. | 0,8 Mio · 0,1 % | 17,8 Mio · 3,1 % | 75,2 % | 22,7 % | 14,63 $ | 0,60 $ | 7,22 $ |
| 2020 | 25,42 Mrd. | 7,26 Mrd. | 12,31 $ | 590 Mio. | 0,8 Mio · 0,1 % | 19,8 Mio · 3,4 % | 75,8 % | 28,6 % | 16,76 $ | 0,56 $ | 6,56 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 10,05 Mrd. | 2,38 Mrd. | 4,37 $ | 544 Mio. | 23,6 % | 6,41 $ |
| Q1 2026 | 8,62 Mrd. | 1,82 Mrd. | 3,34 $ | 544 Mio. | 21,1 % | 2,72 $ |
| Q4 2025 | 9,87 Mrd. | 1,33 Mrd. | 2,46 $ | 543 Mio. | 13,5 % | 1,77 $ |
| Q3 2025 | 9,56 Mrd. | 3,22 Mrd. | 5,93 $ | 542 Mio. | 33,7 % | 7,84 $ |
| Q2 2025 | 9,18 Mrd. | 1,43 Mrd. | 2,65 $ | 541 Mio. | 15,6 % | 3,53 $ |
| Q1 2025 | 8,15 Mrd. | 1,73 Mrd. | 3,20 $ | 541 Mio. | 21,2 % | 1,81 $ |
| Q4 2024 | 9,09 Mrd. | 627 Mio. | 1,16 $ | — | 6,9 % | 8,12 $ |
| Q3 2024 | 8,5 Mrd. | 2,83 Mrd. | 5,22 $ | 542 Mio. | 33,3 % | 6,11 $ |
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
UPLIZNA Market Poised for Growth Through 2034 as Expanding Indications and Rising Demand Drive Sales Opportunities
Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease
Amgen price target raised by Jefferies to $410 after positive Sjögren's data
Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and commercializes human therapeutics. Its current portfolio focuses on serious diseases across oncology, cardiovascular disease, inflammation, bone health, nephrology, and rare diseases, with medicines delivered through biologics such as recombinant proteins and monoclonal antibodies. Amgen works with healthcare providers, hospitals, pharmacies, and wholesalers, serving patients in developed markets worldwide. The company’s role in the financial market is closely tied to its branded biologic medicines and research-driven product pipeline, which support its position as one of the leading independent biotechnology companies. Headquartered in Thousand Oaks, California, Amgen combines large-scale manufacturing and global distribution with a strong emphasis on innovative treatments for conditions with high unmet medical need.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest AMGN und jede andere Aktie unbegrenzt.